A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors

Maureen Sadim, Yanfei Xu, Katharina Selig, Julie Paulus, Regina Uthe, Surbhi Agarwl, Iram Dubin, Panagiota Oikonomopoulou, Lesya Zaichenko, Silvia Aki McCandlish, Linda Van Horn, Christos Mantzoros, Donna Pauler Ankerst, Virginia G. Kaklamani

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

BACKGROUND: Postdiagnosis weight gain in patients with breast cancer has been associated with increased cancer recurrence and mortality. This study was designed to identify risk factors for weight gain and create a predictive model to identify a high-risk population for targeted interventions. METHODS: The weight of 393 patients with breast cancer from the Northwestern Robert H. Lurie Cancer Center was measured over a 2-year period from diagnosis, with body mass index (BMI) change over 18 months as the primary endpoint. Demographics, clinical factors, treatment methods, as well as tumor characteristics were also recorded; and a lifestyle questionnaire was conducted. Blood samples were genotyped for 16 single nucleotide polymorphisms in FTO, adiponectin pathway genes (ADIPOQ, ADIPOR1), and FNDC5. Serum leptin, adiponectin, and irisin levels also were measured. RESULTS: Mean ± standard deviation 18-month BMI changes were 0.68 ± 1.42, 0.98 ± 1.62, 0.79 ± 1.74, and −0.44 ± 1.58 kg/m2 for patients ages <40, 40 to 49, 50 to 59, and ≥60 years, respectively. The optimal multivariable model for 18-month BMI change contained the predictors age, height, and endocrine therapy, but only age was statistically significant, with a 0.04 kg/m2 increase in 18-month BMI change per younger year of age. Single nucleotide polymorphisms in ADIPOR1, FTO, and FNDC5 were associated with 18-month BMI change, and the first 2 remained significant after adjusting for the optimal clinical model (all P <.05). CONCLUSIONS: Women age 60 years and younger at the time of breast cancer diagnosis who have an obesity genetic risk model are at increased risk for weight gain after treatment and should be targeted for weight-maintenance interventions. Cancer 2017;123:2413–21.

Original languageEnglish (US)
Pages (from-to)2413-2421
Number of pages9
JournalCancer
Volume123
Issue number13
DOIs
StatePublished - Jul 1 2017

Keywords

  • adiponectin
  • breast cancer
  • fat mass and obesity-associated gene (FTO)
  • irisin
  • weight gain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors'. Together they form a unique fingerprint.

Cite this